Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.

Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key drugs Wegovy and ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy ...

Novo Nordisk (NVO) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy injection 0.25 ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket. The deal is available through the drugmaker's new NovoCare Pharmacy offering ...